A Novel Risk Scoring System to Predict Survival in Soft Tissue-Related Extramedullary Multiple Myeloma

Objective: Extramedullary multiple myeloma (EMM) is an aggressive subtype of multiple myeloma, especially those soft tissue-related extramedullary multiple myeloma (EM-S). Plasma cells often infiltrate in extramedullary tissues, but the proportion of plamas cells in bone marrow is not high, so FISH...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2021-11, Vol.138 (Supplement 1), p.4749-4749
Hauptverfasser: Huang, Beihui, Wang, Qing, Li, Wuping, Zhao, Ying, Li, Juan
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4749
container_issue Supplement 1
container_start_page 4749
container_title Blood
container_volume 138
creator Huang, Beihui
Wang, Qing
Li, Wuping
Zhao, Ying
Li, Juan
description Objective: Extramedullary multiple myeloma (EMM) is an aggressive subtype of multiple myeloma, especially those soft tissue-related extramedullary multiple myeloma (EM-S). Plasma cells often infiltrate in extramedullary tissues, but the proportion of plamas cells in bone marrow is not high, so FISH test often produces false negative results. Therefore, the R-ISS staging system cannot predict the really prognosis of this type of patients. A novel risk score is needed for these patients. Methos: A cohort of 73 patients with EM-S in four centers in China were included, excluding those only with bone related extramedullary multiple myeloma, primary or secondary plasma leukemia. We performed univariate and multivariate Cox regression analysis, generated risk scores to predict outcomes in EM-S MM and compared with R-ISS staging. Results: In the Cox multivariate model, high LDH, low count of platelet、central nervous system involved, abdominal viscera involved (including liver, spleen, pancreas, kidney) and Ki67≥70% were found to significantly and independently predict outcomes for EM-S. According to these parameters, the patients were divided into three groups: the low-risk group with a median TTP of 14.13 months, and the medium-risk group with a median TTP of 8.53 months. In the high-risk group, the median TTP was 2.73 months (p
doi_str_mv 10.1182/blood-2021-144837
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2021_144837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497121066465</els_id><sourcerecordid>S0006497121066465</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1377-a79799ad6c11fd95c53c728197180f61a8ce3ce6b23209643f13d5cbaca554b33</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMoWKsP4C4vEM1lrrgqxRu0Kp26DpnkjEQzTUkyxb69U-va1Vl9h-__ELpm9Iaxit-2zntDOOWMsCyrRHmCJiznFaGU01M0oZQWJKtLdo4uYvyklGWC5xPUzfCL34HDKxu_cKN9sJsP3Oxjgh4nj98CGKsTboawszvlsN3gxncJr22MA5AVOJXA4PvvFFQPZnBOhT1eDi7ZrQO83IPzvbpEZ51yEa7-7hS9P9yv509k8fr4PJ8tiGaiLIkq67KulSk0Y52pc50LXfKKjd4V7QqmKg1CQ9FywWldZKJjwuS6VVrledYKMUXs-FcHH2OATm6D7Ucjyag8hJK_oeQhlDyGGpm7IwOj2M5CkFFb2OhxeACdpPH2H_oHDehxlA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Novel Risk Scoring System to Predict Survival in Soft Tissue-Related Extramedullary Multiple Myeloma</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Huang, Beihui ; Wang, Qing ; Li, Wuping ; Zhao, Ying ; Li, Juan</creator><creatorcontrib>Huang, Beihui ; Wang, Qing ; Li, Wuping ; Zhao, Ying ; Li, Juan</creatorcontrib><description>Objective: Extramedullary multiple myeloma (EMM) is an aggressive subtype of multiple myeloma, especially those soft tissue-related extramedullary multiple myeloma (EM-S). Plasma cells often infiltrate in extramedullary tissues, but the proportion of plamas cells in bone marrow is not high, so FISH test often produces false negative results. Therefore, the R-ISS staging system cannot predict the really prognosis of this type of patients. A novel risk score is needed for these patients. Methos: A cohort of 73 patients with EM-S in four centers in China were included, excluding those only with bone related extramedullary multiple myeloma, primary or secondary plasma leukemia. We performed univariate and multivariate Cox regression analysis, generated risk scores to predict outcomes in EM-S MM and compared with R-ISS staging. Results: In the Cox multivariate model, high LDH, low count of platelet、central nervous system involved, abdominal viscera involved (including liver, spleen, pancreas, kidney) and Ki67≥70% were found to significantly and independently predict outcomes for EM-S. According to these parameters, the patients were divided into three groups: the low-risk group with a median TTP of 14.13 months, and the medium-risk group with a median TTP of 8.53 months. In the high-risk group, the median TTP was 2.73 months (p&lt;0.05 between any two groups). This novel risk is better to predict prognosis of this group of patients than R-ISS stage, in which the TTP in R-ISS stage I was 20.33 months, R-ISS stage II 9.83 months, and R-ISS stage III 4.83 months (p=0.065). Conclusion: The novel risk stratification for EM-S may be may be superior to R-ISS for EM-S MM patients. [Display omitted] No relevant conflicts of interest to declare.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2021-144837</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2021-11, Vol.138 (Supplement 1), p.4749-4749</ispartof><rights>2021 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Huang, Beihui</creatorcontrib><creatorcontrib>Wang, Qing</creatorcontrib><creatorcontrib>Li, Wuping</creatorcontrib><creatorcontrib>Zhao, Ying</creatorcontrib><creatorcontrib>Li, Juan</creatorcontrib><title>A Novel Risk Scoring System to Predict Survival in Soft Tissue-Related Extramedullary Multiple Myeloma</title><title>Blood</title><description>Objective: Extramedullary multiple myeloma (EMM) is an aggressive subtype of multiple myeloma, especially those soft tissue-related extramedullary multiple myeloma (EM-S). Plasma cells often infiltrate in extramedullary tissues, but the proportion of plamas cells in bone marrow is not high, so FISH test often produces false negative results. Therefore, the R-ISS staging system cannot predict the really prognosis of this type of patients. A novel risk score is needed for these patients. Methos: A cohort of 73 patients with EM-S in four centers in China were included, excluding those only with bone related extramedullary multiple myeloma, primary or secondary plasma leukemia. We performed univariate and multivariate Cox regression analysis, generated risk scores to predict outcomes in EM-S MM and compared with R-ISS staging. Results: In the Cox multivariate model, high LDH, low count of platelet、central nervous system involved, abdominal viscera involved (including liver, spleen, pancreas, kidney) and Ki67≥70% were found to significantly and independently predict outcomes for EM-S. According to these parameters, the patients were divided into three groups: the low-risk group with a median TTP of 14.13 months, and the medium-risk group with a median TTP of 8.53 months. In the high-risk group, the median TTP was 2.73 months (p&lt;0.05 between any two groups). This novel risk is better to predict prognosis of this group of patients than R-ISS stage, in which the TTP in R-ISS stage I was 20.33 months, R-ISS stage II 9.83 months, and R-ISS stage III 4.83 months (p=0.065). Conclusion: The novel risk stratification for EM-S may be may be superior to R-ISS for EM-S MM patients. [Display omitted] No relevant conflicts of interest to declare.</description><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kMtKAzEUhoMoWKsP4C4vEM1lrrgqxRu0Kp26DpnkjEQzTUkyxb69U-va1Vl9h-__ELpm9Iaxit-2zntDOOWMsCyrRHmCJiznFaGU01M0oZQWJKtLdo4uYvyklGWC5xPUzfCL34HDKxu_cKN9sJsP3Oxjgh4nj98CGKsTboawszvlsN3gxncJr22MA5AVOJXA4PvvFFQPZnBOhT1eDi7ZrQO83IPzvbpEZ51yEa7-7hS9P9yv509k8fr4PJ8tiGaiLIkq67KulSk0Y52pc50LXfKKjd4V7QqmKg1CQ9FywWldZKJjwuS6VVrledYKMUXs-FcHH2OATm6D7Ucjyag8hJK_oeQhlDyGGpm7IwOj2M5CkFFb2OhxeACdpPH2H_oHDehxlA</recordid><startdate>20211123</startdate><enddate>20211123</enddate><creator>Huang, Beihui</creator><creator>Wang, Qing</creator><creator>Li, Wuping</creator><creator>Zhao, Ying</creator><creator>Li, Juan</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20211123</creationdate><title>A Novel Risk Scoring System to Predict Survival in Soft Tissue-Related Extramedullary Multiple Myeloma</title><author>Huang, Beihui ; Wang, Qing ; Li, Wuping ; Zhao, Ying ; Li, Juan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1377-a79799ad6c11fd95c53c728197180f61a8ce3ce6b23209643f13d5cbaca554b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Beihui</creatorcontrib><creatorcontrib>Wang, Qing</creatorcontrib><creatorcontrib>Li, Wuping</creatorcontrib><creatorcontrib>Zhao, Ying</creatorcontrib><creatorcontrib>Li, Juan</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Beihui</au><au>Wang, Qing</au><au>Li, Wuping</au><au>Zhao, Ying</au><au>Li, Juan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Novel Risk Scoring System to Predict Survival in Soft Tissue-Related Extramedullary Multiple Myeloma</atitle><jtitle>Blood</jtitle><date>2021-11-23</date><risdate>2021</risdate><volume>138</volume><issue>Supplement 1</issue><spage>4749</spage><epage>4749</epage><pages>4749-4749</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Objective: Extramedullary multiple myeloma (EMM) is an aggressive subtype of multiple myeloma, especially those soft tissue-related extramedullary multiple myeloma (EM-S). Plasma cells often infiltrate in extramedullary tissues, but the proportion of plamas cells in bone marrow is not high, so FISH test often produces false negative results. Therefore, the R-ISS staging system cannot predict the really prognosis of this type of patients. A novel risk score is needed for these patients. Methos: A cohort of 73 patients with EM-S in four centers in China were included, excluding those only with bone related extramedullary multiple myeloma, primary or secondary plasma leukemia. We performed univariate and multivariate Cox regression analysis, generated risk scores to predict outcomes in EM-S MM and compared with R-ISS staging. Results: In the Cox multivariate model, high LDH, low count of platelet、central nervous system involved, abdominal viscera involved (including liver, spleen, pancreas, kidney) and Ki67≥70% were found to significantly and independently predict outcomes for EM-S. According to these parameters, the patients were divided into three groups: the low-risk group with a median TTP of 14.13 months, and the medium-risk group with a median TTP of 8.53 months. In the high-risk group, the median TTP was 2.73 months (p&lt;0.05 between any two groups). This novel risk is better to predict prognosis of this group of patients than R-ISS stage, in which the TTP in R-ISS stage I was 20.33 months, R-ISS stage II 9.83 months, and R-ISS stage III 4.83 months (p=0.065). Conclusion: The novel risk stratification for EM-S may be may be superior to R-ISS for EM-S MM patients. [Display omitted] No relevant conflicts of interest to declare.</abstract><pub>Elsevier Inc</pub><doi>10.1182/blood-2021-144837</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2021-11, Vol.138 (Supplement 1), p.4749-4749
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2021_144837
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title A Novel Risk Scoring System to Predict Survival in Soft Tissue-Related Extramedullary Multiple Myeloma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T07%3A44%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Novel%20Risk%20Scoring%20System%20to%20Predict%20Survival%20in%20Soft%20Tissue-Related%20Extramedullary%20Multiple%20Myeloma&rft.jtitle=Blood&rft.au=Huang,%20Beihui&rft.date=2021-11-23&rft.volume=138&rft.issue=Supplement%201&rft.spage=4749&rft.epage=4749&rft.pages=4749-4749&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2021-144837&rft_dat=%3Celsevier_cross%3ES0006497121066465%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497121066465&rfr_iscdi=true